Healthcare Services

Renal Biomarkers Market Growth Expected to Reach $2.04 Billion by 2030 with 8.2% CAGR

April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Renal Biomarkers Market In 2026 And What Value Is Projected For 2030?

The renal biomarkers market has experienced substantial growth over recent years. It is forecasted to expand from $1.37 billion in 2025 to $1.49 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.6%. The historical growth of this market can be attributed to several factors, including the increasing prevalence of chronic kidney disease, a greater use of creatinine and urea testing, the expansion of diagnostic laboratory infrastructure, a growing awareness about early kidney injury detection, and advancements in immunoassay technologies.

The renal biomarkers market is anticipated to exhibit robust growth in the coming years, with its valuation expected to reach $2.04 billion by 2030, advancing at a compound annual growth rate (CAGR) of 8.2%. This projected expansion during the forecast period is primarily driven by the increasing integration of precision medicine approaches, a rising need for predictive diagnostics in renal health, the enlargement of biomarker-centric clinical research, the growing incorporation of AI in biomarker analysis, and an intensified focus on personalized nephrology care. Significant trends influencing this period include the wider adoption of novel biomarkers for kidney injury, an increasing utilization of multi-biomarker panels in diagnostic procedures, a heightened demand for the early detection of kidney damage, the expansion of non-invasive urine-based testing, and an enhanced emphasis on tracking disease progression.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7711&type=smp

What Drivers Are Influencing The Renal Biomarkers Market?

The escalating prevalence of chronic kidney disease (CKD) is projected to fuel expansion in the renal biomarkers market. CKD represents a protracted ailment marked by a progressive decrease in kidney function, hindering the body’s capacity to filter waste, sustain fluid equilibrium, and control vital electrolytes. This rising incidence of CKD stems primarily from an aging global demographic, diabetes, high blood pressure, and genetic predispositions, factors that collectively lead to elevated rates of kidney complications and fatalities. In clinical settings, renal biomarkers are vital for facilitating prompt diagnosis, tracking the advancement of the disease, and aiding in swift therapeutic actions to avert kidney failure. An example of this impact is seen in December 2024, when the Australian Institute of Health and Welfare, an Australia-based government agency, reported that chronic kidney disease constituted 1.1% of Australia’s overall disease burden, with age-adjusted data indicating that males bore a burden 1.3 times greater than females. Consequently, the increasing impact of chronic kidney disease is a key impetus for the expansion of the renal biomarkers market.

What Are The Key Segments Of The Renal Biomarkers Market?

The renal biomarkers market covered in this report is segmented –

1) By Biomarker Type: Functional Biomarker, Up Regulated Protein, Other Biomarker Types

2) By Diagnostic Technique: Enzyme-Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LS-MS)

3) By Application: Diagnosis And Disease Progression Monitoring, Clinical Research

4) By End User: Hospitals, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Functional Biomarker: Creatinine, Urea, Cystatin C, Bicarbonate

2) By Up Regulated Protein: Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), Interleukin-18 (IL-18)

3) By Other Biomarker Types: Proximal Tubule Injury Biomarkers, Acute Kidney Injury Biomarkers, Chronic Kidney Disease Biomarkers

What Trends Are Affecting The Expansion Of The Renal Biomarkers Market?

Companies operating within the renal biomarkers market are increasingly establishing advanced collaborations with research organizations and AI-driven biotechnology firms. These partnerships aim to enhance biomarker discovery, improve patient stratification, and strengthen precision diagnostic capabilities. The strategic alliances seek to accelerate the identification and validation of novel biomarkers, supporting early disease detection, refined risk assessment, and personalized treatment approaches for kidney disorders. For instance, in November 2024, MultiOmic Health, an AI-powered drug discovery company based in the UK, identified novel patient endotypes and proprietary biomarkers for diabetic kidney disease (DKD) through a research collaboration with the Northern Care Alliance NHS Foundation Trust. These biomarkers facilitate precise patient segmentation and enable the development of targeted diagnostic tools and therapeutics, thereby supporting improved clinical decision-making and outcomes in kidney care.

Who Are The Leading Companies Operating In The Renal Biomarkers Market?

Major companies operating in the renal biomarkers market are Abbott Laboratories, BioPorto Diagnostics A S, Roche Holding AG, Thermo Fisher Scientific, bioMérieux SA, Randox Laboratories, Siemens Healthineers, Beckman Coulter Inc., Astute Medical Inc., Sphingotec GmbH, Bio Rad Laboratories India Pvt. Ltd., Enzo Biochem Inc., PerkinElmer Inc., Alere Inc., Bio Techne Corp., DiaSorin S.p.A., EKF Diagnostics Holdings plc, Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Merck KGaA, Myriad RBM Inc., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, R And D Systems Inc., Roche Diagnostics International Ltd, Sekisui Chemical Co. Ltd., Sysmex Corporation, Tosoh Bioscience Inc.

Read the full renal biomarkers market report here:

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Renal Biomarkers Market?

North America was the largest region in the renal biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered in the renal biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Renal Biomarkers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7711&type=smp

Browse Through More Reports Similar to the Global Renal Biomarkers Market 2026, By The Business Research Company

Robotic Surgery Services Global Market Report

https://www.thebusinessresearchcompany.com/report/robotic-surgery-services-global-market-report

Non Surgical Cosmetic Procedures Global Market Report

https://www.thebusinessresearchcompany.com/report/non-surgical-cosmetic-procedures-global-market-report

Surgical Robots Global Market Report

https://www.thebusinessresearchcompany.com/report/surgical-robots-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795